diagnost tool
price close busi septemb
anim health diagnost compani
seek take modest us market share gain
expand intern time
convert note offer help enabl global
expans trim estim price target
appear third consecut bridg year result
remov top pick list even announc
price million convert senior note due believ
help compani fund new product launch expand commerci across
europ like fund hand small acquisit help scale across
europ beyond view financ overdu compani
oper time cash balanc hover around million trim
year revenu earn estim exercis conservat
top line growth expect higher level spend help return compani
growth follow year miss expect cautious optimist see
deliv growth initi howev near-term expect temper
see evid stronger commerci execut trim estim
price target stick buy rate hope see
progress new product geograph expans look
convert note convert note bear interest matur
total net proce open gamut
make one acquisit acceler intern expans taken
longer come fruition expect
strategi approach intern strategi country-
initi organ germani spain benelux scandinavia uk recal
acquir optom revenu think hand deal
compani could end small larger
element uf commun believ track launch element
uf urin fecal analyz target meanwhil hope launch
element rc rotor chemistri ou help goal becom global
vet diagnost compani help drive greenfield account win specif less
sophist intern vet practic squar footag limit
long-term target plan updat lt target call
provid specif expect lower previous
commun lt target rev y/i om vs
today rev om compar
think revenu target could hit acquisit like
base eu expect lower long-term om make invest
scale busi believ prudent invest
corpor account traction mix pleas roll new custom
etho behind ship pet vet center pvcc plan
convert pvcc instal expect someth consider lower
catalyst modest lift launch rotor chemistri ou element multiplex
immunodiagnost analyz news ou expans new tuck-in
larger deal launch urine-fec uf analyz
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
lower estim price target price target use multipl
revenu estim discount back year discount rate
use million dilut share outstand formerli price target use
multipl revenu estim discount back year
discount rate use dilut share outstand lower out-year
revenu earn estim primarili take cautiou view exist
new product revenu bucket addit slightli higher oper expens
believ requir help fund new initi rel prior expect
miss deliv revenu y/i miss y/
consum rev beat instrument
imag miss us respect deliv loss
oper margin function declin rev higher spend
companion rev miss poc instrument
miss imag rev miss
pvd ovp togeth rev rev
guid call reiter revenue guid y/
core rev revenue guid y/i off-set non-cor
rev y/i core reiter guid
growth consum growth us imag rev growth
ou imag rev includ rev acquir franc busi
reiter opex y/i om
ou expans recent tuck-in acquisit franc februari
close acquisit optom france-bas compani design develop
manufactur distribut vet imag product primari focu endoscopi
optom gener rev million euro employe
acquir busi modest sum resourc give
busi beachhead franc see variou opportun across
europ similar other much larger see quit
opportun ou bolt tuck-in tune rev thu
think like remain acquisit recent mention
see opportun acquir revenu one sever possibl
deal ou busi build australia expect modest revenu
contribut also target new partner middl east ukrain
eastern europ select asian countri doesnt coverag
zts/abax impact recent indic see chang field
result zts-abax merger suggest earli think abax
longer donor point share year point share donor
split zts/abax team bundl rotor therapeut
also opin acquir abaxi acceler abil test treat
larg anim health player could follow suit impli mar acquir vca antech
boehring ingelheim bi rev acquir merial anoth
global anim health compani like elanco merck bayer hillhous china
market share dynam earlier year estim market share
anim health diagnost unit state abaxi
noth estim terribl differ
trail survey data suggest abaxi
none/greenfield caution data come
survey respons time tini fraction clinic us
survey data also repres averag last three year like exclud
abaxi recent share loss recent share gain link
recent anim health survey found
move forward combin urin fecal analyz togeth onto one
platform part result combin two expect launch uf
mark delay rel time announc may analyst day
compani origin commun urin fecal
think new product set possibl good growth inflect think
might mark growth compani execut intern expans
buy unchang target price septemb
diagnost tool
possibl addit acquisit benefit traction new product coupl
possibl market share gain unit state
element uf look provid automat imag annual urin sediment
exam manual point-of-car fecal flotat exam complet year
expect launch serv industri first dual urine-fec analyz
size combin opportun urin fecal
indic valid abil combin urin fecal onto one
analyz indic product launch near term
excit uf
hope near term lift launch element rc rotor-bas chemistri
analyz ou market element multiplex immunodiagnost
platform recent launch
hska element rc analyz design primarili ou custom first-tim
user chemistri analyz element rc abil run test
rotor vs abaxi tests/rotor view competit advantag
compar legaci non-multiplex immunodiagnost platform element
lower cost faster higher sensit allow multiplex
intend launch element total cortisol assay
compris revenu flow legaci immunodiagnost box
intend launch test heartworm lyme anaplasma ehrlichia
like opinion view test
roughli custom long-term subscript model six-year
term agreement tend monthli minimum
annual price escal target activ subscrib
indic corpor vet hospit us vs
nascent chines market point rise interest veterinari invest
china evidenc hillhous capit group one china largest ventur fund
acquisit chines vet hospit
buy unchang target price septemb
diagnost tool
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
buy unchang target price septemb
diagnost tool
buy unchang target price septemb
diagnost tool
